Edap Tms (NASDAQ:EDAP) Shares Pass Above 200-Day Moving Average – Here’s What Happened

Edap Tms S.A. (NASDAQ:EDAP) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.59 and traded as high as $4.47. Edap Tms shares last traded at $4.32, with a volume of 55,873 shares.

Wall Street Analyst Weigh In

A number of research firms have issued reports on EDAP. Wall Street Zen lowered Edap Tms from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. HC Wainwright reduced their price objective on Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $6.00.

Edap Tms Stock Up 2.9%

The firm’s 50-day simple moving average is $3.74 and its 200-day simple moving average is $3.59. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. The company has a market capitalization of $161.91 million, a price-to-earnings ratio of -5.33 and a beta of -0.10.

Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). Edap Tms had a negative net margin of 41.47% and a negative return on equity of 137.61%. The company had revenue of $20.48 million for the quarter, compared to analyst estimates of $19.46 million. Sell-side analysts forecast that Edap Tms S.A. will post -0.82 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Joshua Levine acquired 10,000 shares of Edap Tms stock in a transaction on Monday, May 11th. The stock was bought at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the transaction, the director owned 35,000 shares of the company’s stock, valued at $147,700. The trade was a 40.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 10.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Financial Planning Navigators CORP bought a new stake in Edap Tms in the 4th quarter valued at $33,000. Leonteq Securities AG bought a new position in shares of Edap Tms during the 4th quarter worth about $313,000. Kovack Advisors Inc. acquired a new stake in shares of Edap Tms during the 4th quarter valued at about $53,000. Rock Springs Capital Management LP boosted its position in shares of Edap Tms by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock valued at $4,233,000 after acquiring an additional 16,500 shares in the last quarter. Finally, Flax Pond Capital LLC bought a new stake in Edap Tms in the fourth quarter valued at about $2,623,000. 62.74% of the stock is owned by institutional investors.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.